quality and affordable protein therapeutics
Amgen、Genentech、Lilly、Applied Molecular Evolution (Eli Lilly)、Bristol-Myers Squibb、Bayer等国际顶级生物医药公司服务多年。他们对新型复杂生物药——包括单克隆抗体及融合蛋白等产品的开发及商品化整套流程具有广泛而丰富的实践及管理经验，无论是在抗体工程、细胞株开发、产程/分析方法开发，还是在GMP生产管理、质量监控、临床研究、全球药政事务等方面都有深厚造诣和产业界实务经验。
Kun-Liang Guan, Chairman of Henlius Scientific Advisory Board, is a Distinguished Professor of Pharmacology at the University of California, San Diego. He obtained his BS (1982) at Hangzhou University, China and PhD (1989) at Purdue University. From 1992-2007, Guan was a faculty at the University of Michigan. He received the MacArthur Fellowship, the American Society of Biochemistry and Molecular Biology Young Investigator Award, Distinguished Alumni Award from Purdue University, an AAAS Fellow, and is a highly cited researcher in Molecular Biology & Genetics (Thomson Reuters). Guan studies signaling mechanisms of cell growth and tumorigenesis, particular focusing on the mTOR and Hippo pathways.
Yiping Yang, member of Henlius Scientific Advisory Board, received his M.D. from Zhejiang University, and Ph.D. from University of Michigan. He then completed his postdoctoral training and Internal Medicine residency at the University of Pennsylvania, and his Medical Oncology fellowship at Johns Hopkins University. He is an ABIM-certified physician with clinical interest in lymphoma and leukemia. He has been selected as America’s top oncologist since 2008. Funded by grants from National Institute of Health and private foundations, his research focuses on cancer immunology and immunotherapy, as well as gene therapy and viral immunity. He has published more than 100 peer-reviewed papers in journals including Science, Nature Immunology, Nature Genetics, Nature Medicine, Immunity, JCI, PNAS, etc.
Weiping Zou, member of Henlius Scientific Advisory Board, is a faculty at the University of Michigan. His research interests are in tumor immunopathology and immunotherapy. Over the past few years, his research team has achieved important insights into cancer immunopathogenesis. His research efforts demonstrate that the tumor microenvironment is comprised of immune cells that have been reprogrammed by active tumor-mediated processes to defeat tumor immunity and promote tumor progression in a highly effective manner. These studies have helped define the nature of immune responses in the cancer microenvironment, form the concept of immunosuppressive networks in the cancer microenvironment and provide significant insights into designing current immune therapies including inhibitory B7 checkpoint blockade (PD-L1, B7-H1) to treat cancer patients. The Zou laboratory is one of the most cited research teams in the field of Cancer Immunology. Dr. Zou is/was an editorial board member for 9 scientific journals. He has delivered more than 200 invited lectures. He serves as a reviewer for more than 15 funding agencies including NIH and DOD, and for more than 50 scientific journals including New England Journal of Medicine, Cell, Science, and Nature journals. He is the AACR Cancer Immunology Chairperson-elect 2018-2019.
Zihai Li, member of Henlius Scientific Advisory Board, received his medical degree from Henan Medical University and Peking Union Medical College, and his Ph.D. in Microbiology & Immunology from Icahn School of Medicine at Mount Sinai, New York. He finished his residency training in Internal Medicine at Montefiore-Einstein Medical Center, Albert Einstein College of Medicine, and completed his fellowship in Medical Oncology at Fred Hutchinson Cancer Research Center, University of Washington.Dr. Li’s areas of expertise include cancer immunology, immune tolerance, and functions of endoplasmic reticulum chaperones in cancer biology and therapy. The current work of the Li laboratory focuses on developing better immune therapeutics in the forms of antibodies, adoptive T cell transfer and immune checkpoint blockers, aiming to reverse and reprogram the tolerogenic tumor microenvironment for cancer cure. Fundamental mechanisms of immune regulation are being studied in parallel. Dr. Zihai Li is an elected member of two prestigious physician scientist honor societies: American Society of Clinical Investigation (ASCI) and Association of American Physicians (AAP).